DELAFIELD, Wis. (Stockpickr) -- As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Lion Biotechnologies

Lion Biotechnologies (LBIO) , a clinical-stage biopharmaceutical company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. This stock is trading up 6.2% to $6.38 in Thursday's trading session.

  • Thursday's Range: $6.03-$6.52
  • 52-Week Range: $4.97-$15.03
  • Thursday's Volume: 90,000
  • Three-Month Average Volume: 461,418

From a technical perspective, Lion Biotechnologies is ripping notably higher here right off some near-term support at $6 and back above its 20-day moving average of $6.36 with lighter-than-average volume. This stock has been uptrending a bit over the last few weeks, with shares moving higher from its low of $5.27 to its recent high of $6.83 a share. During that uptrend, shares of Lion Biotechnologies have been making mostly higher lows and higher highs, which is bullish technical price action. This spike to the upside on Thursday is now quickly pushing this stock within range of triggering a major breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out its 50-day moving average of $6.79 to more key resistance levels at $6.83 to $7 a share with high volume.

Traders should now look for long-biased trades in Lion Biotechnologies as long as it's trending some near-term support at $6 and then once it sustains a move or close above those breakout levels with volume that hits near or above 461,418 shares. If that breakout triggers soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $7.50 to $8.27, or even $9 a share.

Amicus Therapeutics

Amicus Therapeutics (FOLD) - Get Report , a biopharmaceutical company, develops and commercializes therapeutic products for rare and orphan diseases. This stock is trading up 4.9% to $7.06 in Thursday's trading session.

  • Thursday's Range: $6.64-$7.16
  • 52-Week Range: $5.22-$18.83
  • Thursday's Volume: 1.18 million
  • Three-Month Average Volume: 3.61 million

From a technical perspective, Amicus Therapeutics is spiking sharply higher here right off some near-term support at $6.61 with decent upside volume flows. This stock recently entered extremely oversold territory, after its current relative strength index reading printed well below 30. Oversold can always get more oversold, but shares of Amicus Therapeutics are now starting to spike higher off some near-term support and it's quickly moving within range of triggering a big breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $7.71 to $7.84 a share with high volume.

Traders should now look for long-biased trades in Amicus Therapeutics as long as it's trending above some near-term overhead resistance levels at $6.61 or around $6 and then once it sustains a move or close above those breakout levels with volume that hits near or above 3.61 million shares. If that breakout develops soon, then this stock will set up to re-test or possibly take out its next major overhead resistance level at its gap-down-day high from earlier this month at $10 a share.

Affimed

Affimed (AFMD) - Get Report , a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. This stock is trading up 13.1% to $6.95 Thursday's trading session.

  • Thursday's Range: $6.27-$7.26
  • 52-Week Range: $3.55-$24.20
  • Thursday's Volume: 377,000
  • Three-Month Average Volume: 247,923

From a technical perspective, Affimed are soaring sharply higher here right above some near-term support at $6 a share with above-average volume. This stock has been attempting to carve out a double bottom chart pattern over the last few weeks, with shares finding some buying interest at $5.80 to $6 a share. This potential bottom is coming after shares of Affimed downtrended badly off its July high of $24.20 to that recent low of $5.80 a share. This high-volume spike higher on Thursday is now starting to push this stock back above its 20-day moving average of $6.98 and it's quickly moving it within range of triggering a major breakout trade above some key near-term overhead resistance levels. That breakout will trigger if this stock manages to take out some near-term overhead resistance levels at $7.55 to around $8 a share with high volume.

Traders should now look for long-biased trades in Affimed as long as it's trending above those recent double bottom support levels and then once it sustains a move or close above those breakout levels with volume that registers near or above 247,923 shares. If that breakout gets set off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at its 50-day moving average of $9.03 to its 200-day moving average of $9.28, or even $10.62 to $10.70 a share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.